Quick Med Technologies Inc (CE) (QMDT) Quote

Riding!!!!!!!!!!!

Ride or die baby! Long term investor. Solid products with military contracts.

Anybody still playing this?

You still in this one?

Some unusual volume the last few days. Is someone accumulating?

New website https://www.oxi-tex.com/

this patent could be valuable now...

I agree, no reason for the silence. I have emailed the company several times and have never received a single response. They are very obviously still doing business, and must be doing fairly well because they don't need the market to survive. They should either update shareholders or take the company private through a buyout.

$QMDT update their website: © Copyright 2019 Quick-Med Technologies, Inc. Corporate Website Design by Equisolve

This is an Amazing company should trade a hell lot higher. I don't understand why they go silent for the past 5 years?

Quick-Med’s patented technology, received de Novo FDA clearance in June 2009 what a waste opportunity.
https://www.quickmedtech.com/technology/nimbus


https://www.quickmedtech.com/

Quick-Med Technologies, Inc.
902 NW 4th Street
Gainesville, Florida 32601-4285

Corporate Number: 352-379-0611
Fax: 352-379-1099

Email: info@quickmedtech.com

Website: www.quickmedtech.com

QMDT still current and active with NVSOS:

https://www.nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=uqPeK5X78e8FSS496vfYYw%253d%253d&nt7=0

Too bad the company refuses to share any info with shareholders. They should take the company private if they can't or won't give company updates of any kind.

I would love to see this company re-start their filings and give shareholders some kind of an update. If anybody lives near Gainsville, FL stop by and see what Quick-Med is up to.

Since QMDT is getting some volume today, and just in case anybody is interested, here is a list of patents from Quick-Med. Some of these patents were granted in 2018, so it's clear the company is still active even though the stock is a sleeper and the company had filed to go dark in 2013. Here are the patents:

https://patents.justia.com/assignee/quick-med-technologies-inc

Hi all, new here! Is QMDT not trading? Placed 5K Order via Schwab but nothing happens... Thanks

looking way up,spread is massive, super low float. Undervalued- should work its way higher. $QMDT

dang . . i was the one that found this patent. wish i held

Yep, too much good info on this company, but nobody cares to post or do any DD.

Just you and me hanging out here. lol:))

http://www.innovationintextiles.com/dryeing-finishing-printing/the-best-antimicrobial-technology-that-youve-never-heard-of/

7th March 2016, Hendersonville, NC
The Best Antimicrobial Technology That You’ve Never Heard Of
4 comments

Today’s antimicrobial treatments for textiles are usually marketed based on the concept of odour control, particularly for active and outdoor wear; and on the idea that textiles treated with antimicrobial agents can be washed less frequently.

But most consumers don’t really understand the chemistry of antimicrobial technologies; and those of us who are somewhat informed are vaguely uncomfortable with the idea of substances such as triclosan, quat-silane, and nano-silver applied to textiles that we wear against the skin.
Quick-Med Technologies has developed an antimicroial technology for textiles using hydrogen peroxide. © Quick-Med Technologies

What if there was an antimicrobial technology for textiles that is cost-effective yet highly durable; proven in medical wound care yet as consumer-friendly as laundry detergent; and that degrades into nothing more harmful than water and oxygen?

The wide-spread use of such a technology could go a long ways in reducing our global water crisis, according to Quick-Med Technologies, Inc., a publicly-traded life sciences company based in Florida that is focused on developing technologies for infection prevention and control for the healthcare and consumer markets.
Hydrogen peroxide, a natural antiseptic

According to David Lerner, founder of Quick-Med Technologies, that technology is currently available as a textile finish that is easily applied during the manufacturing process; or can even be applied to finished textiles as a post-treatment. It’s called Oxi Fresh™; and although it has no relationship to the laundry detergent OxiClean™, both are based on hydrogen peroxide (H202), recognized as a safe antimicrobial agent by the US Food and Drug Administration (FDA).

Consumers are familiar with hydrogen peroxide, Lerner pointed out, as a color-safe bleaching agent and stain fighter for laundering applications. Hydrogen peroxide functions by destroying the cell membrane as well as internal cell structures, thereby killing the microbe and inhibiting the growth of microbial colonies.

Hydrogen Peroxide is well-established as a safe and natural antimicrobial. © Quick-Med Technologies

Hydrogen peroxide has been proven to not only reduce the risk of infection dramatically, but to control microbe-driven odour and staining on textiles. Independent lab analysis using AATCC 100 showed that H202 delivered broad spectrum efficacy against a range of common pathogens and odour-causing bacteria.
Rebranding for consumer textiles

Oxi Fresh™ is, in essence, a consumer-facing rebranding of the company’s Stay-Fresh® technology: a hydrogen peroxide bleach that is permanently bound to textiles for consumer use. But whilst the concentration of H202 in antiseptics for medical use is about 3%, the amount used in Oxi Fresh™ is much less concentrated, according to Dr. Bernd Liesenfeld, Quick-Med Technologies’ president.

The inert binder is composed of zinc oxides and hydroxides, which are safely used on sensitive skin in barrier creams such as diaper cream and sunscreen products. Oxi Fresh™ has been validated to retain efficacy for up to 75 launderings at 105° F, with full kill on medical grade bacteria, virus, fungi and mould.

The Environmental Protection Agency (EPA) in the US has registered the Oxi Fresh™ technology for use in a wide range of consumer textile products.

“We feel the degree of testing we’ve done of H202 on wounds and compromised surfaces speaks to an appropriate level of safety,” said Liesenfeld, whose article describing the platform was published in the September/October 2013 edition of the AATCC Review.
Getting the word out to consumers

Quick-Med has licensed their antimicrobial technologies to various consumer and medical textile producers, such as Doris Hosiery, Polartec LLC, Sarasota Medical Products, and Medline. With the rebranding of Stay-Fresh® as Oxi Fresh™, Lerner is looking to take the product to the next level.

An 18-year veteran of the apparel trade, Lerner is focused on the benefits of Oxi Fresh™ to the consumer as well as to the supply chain side of the business. His primary message: textiles treated with Oxi Fresh™ need not be washed as frequently, and can be safely cleaned at lower temperatures, conserving water and energy, whilst conserving the integrity of the product for a longer wearable life.

“Quick-Med Technologies, Inc. has developed and commercialized Oxi Fresh™ as a new, game-changing, green, FDA/EPA-approved antimicrobial and preservative, a ‘No Wash’ product for the textile, apparel, and footwear industries,” Lerner enthused.

Oxi Fresh hopes to reduce the environmental impact of washing consumer textiles. © Quick-Med Technologies

“The average washing machine uses approximately 33 gallons of water per wash,” he continued. “This product will save millions of gallons of water normally used in home laundering and commercial applications.”

Whilst other antimicrobial technologies likewise tout the reduced need for laundering in marketing their products, Oxi Fresh™ would appear to have additional sustainable aspects.

“Oxi Fresh™ performs as well out-of-the-box as it does after 75 home launderings. It is not a heavy metal; it conserves water and energy; and has no detergent runoff into the environment,” Lerner pointed out.

Lerner also believes that Oxi Fresh™ offers potential benefits to the medical and hospitality businesses, where the cost of high-temperature laundering can be very high.
Supply chain positives

The Oxi Fresh™ licensing arrangement “adds pennies on the dollar” to the cost of finished textiles and garments, Lerner insisted. The technology is easily applied, requiring no special equipment, and presenting no discoloration issues.

The finished products stay fresher and cleaner, for longer, as the technology contains an inherent preservative that reduces inventory spoilage due to mould or humidity during transportation and storage.

“Water scarcity is an emerging problem, and getting worse,” Lerner reiterated. “This growing global challenge is creating opportunities for new and advanced textiles. While ‘green’ technologies are often considered more expensive or inconvenient, Oxi Fresh™ delivers real economic and product benefits to provide a win-win for suppliers, consumers, and the environment.”
- See more at: http://www.innovationintextiles.com/dryeing-finishing-printing/the-best-antimicrobial-technology-that-youve-never-heard-of/#sthash.w16auHKC.dpuf

Here is a great read from 2013:
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9634671

This company may have filed to go dark, but they are not defunct by any means. Licenses still issued, patents still getting approved, and still active with NVSOS.

http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=uqPeK5X78e8FSS496vfYYw%253d%253d&nt7=0

BIOGUARD® products employ Nimbus Technology and is licensed to: Derma Sciences, Inc.
In April, 2007, we entered into a license agreement with Derma Sciences Inc. for NIMBUS treatment of select substrates used in traditional wound care. In February, 2009 we received FDA market clearance for the NIMBUS gauze wound dressing licensed to Derma Sciences and in June, 2009 Derma Sciences reported first commercial sale of a product, BIOGUARD® wound dressings, employing our NIMBUS technology. Derma Sciences is marketing and selling the BIOGUARD product to the professional health care market including acute care hospitals, extended care hospitals, nursing homes, and wound care centers. In July 2012, we entered into a new license agreement with Derma Sciences that grants Derma a worldwide (except for India) exclusive license to our NIMBUS treatment of traditional wound dressings in return for $1.3 million in upfront payment, additional milestone payments and ongoing royalty payments.

Here are some of the BIOGUARD® products:







Websites carrying BIOGUARD® products:

http://www.hightidehealth.com/bioguard-barrier-dressings.html

http://www.medline.com/product/SPONGEBIOGUARD-ANTIMICROBIAL-12PL-4X4/Sponges/Z05-PF31309

http://www.dermasciences.com/bioguard-products

http://www.ebay.com/sch/sis.html?_nkw=Bioguard+Gauze+Bandages+97322+Lot+of+6+large+Rolls

http://www.woundsource.com/product/bioguard-barrier-dressings-conforming-bandages

http://www.vitalitymedical.com/bioguard-barrier-dressings.html

http://www.expressmed.com/product/wound-dressings/73959-63151/bioguard-gauze-roll.html

Bernd Liesenfeld

Bernd Liesenfeld

Patents / Publication
Patents / Publication # Year of Publication / Issued Title

8,926,999 2015 Antimicrobial textiles comprising peroxide

8,545,862 2013 Polyelectrolyte complex for imparting antimicrobial properties to a substrate

2013/0011,491 2013 Antimicrobial Textiles Comprising Peroxide

8,277,827 2012 Antimicrobial textiles comprising peroxide

8,092,854 2012 Method of attaching an antimicrobial
cationic polyelectrolyte to the surface of a substrate

2011/0171,280 2011 Antimicrobial Textiles Comprising Peroxide

2010/0330,261 2010 METHOD OF ATTACHING AN ANTIMICROBIAL CATIONIC POLYELECTROLYTE TO THE SURFACE OF A SUBSTRATE

2010/0291,169 2010 Polyelectrolyte Complex for Imparting Antimicrobial Properties to a Substrate

7,790,217 2010 Method of attaching an antimicrobial cationic polyelectrolyte to the surface of a substrate

2009/0181,157 2009 METHOD OF ATTACHING AN ANTIMICROBIAL CATIONIC POLYELECTROLYTE TO THE SURFACE OF A SUBSTRATE

2008/0206,293 2008 Absorbent substrate with a non-leaching antimicrobial activity and a controlled-release bioactive agent.

Quick-Med Technologies
Medical Devices
11-50 employees

The next generation of wound care products won't only cover your wounds, they'll actively kill bacteria and help your body heal itself.

We research & develop long-lasting antimicrobial wound care products with no bacterial resistance. Recently granted FDA cleared and patent approval.

Website

http://www.quickmedtech.com
Industry

Medical Devices
Type

Public Company
Headquarters

902 NW Fourth Street Gainesville, FL 32601 United States
Company Size

11-50 employees

https://www.linkedin.com/company/quickmed-technologies?trk=prof-following-company-logo

Bernd Liesenfeld
President at Quick-Med Technologies
Background
Experience
President
Quick-Med Technologies
2012 – Present (5 years)Gainesville, FL

Principal Scientist
Quick-Med Technologies
2004 – July 2012 (8 years)

https://www.linkedin.com/in/bernd-liesenfeld-3674725

RSI cooled off and gap filled, all on tiny volume.

Anybody seen a stock trade this thin before? I haven't, leads me to believe that the float just might be somewhere around the 1.3 million that I posted earlier.

US Environmental Protection Agency (EPA) has registered Stay Fresh to be utilised to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. Food and Drug Administration (FDA) has also granted clearance to market an antibacterial medical textile based on Stay Fresh Technology.

HOW IT WORKS

Polartec® PolarCare™ blankets utilize the proven freshness enhancing power of Quick-Med Technologies’ Stay Fresh® textile treatment and applies it to our soft and durable synthetic fleece. This unique combination works together to reduce foul odors, stains, and long term fiber deterioration.

The lofted fiber structure provides the highest warmth to weight ratio in performance insulating professional blankets. This construction technique enhances overall blanket breathability to reduce discomfort and perspiration caused from heavy blankets and overheating.

For more information on how Polartec® PolarCare™ blankets can improve your patient's comfort and laundry efficiency contact Tom Lang, langt@polartec.com

http://polartec.com/product/polartec-polarcare-blankets

Polartec LLC uses Stay Fresh® on their blankets:

PolarCare™ Blankets

Polartec® PolarCare™ blankets are engineered specifically for the needs of today's professional textile services. These new blankets provide lighter, softer, and warmer comfort by combining our famous temperature regulating lofted fleece with Stay Fresh® antimicrobial treatment for longer lasting freshness

http://polartec.com/search/result/317a4ace2292743924d7b46b798704ba/

Stay Fresh® Antimicrobial

Stay Fresh® Antimicrobial is a breakthrough antimicrobial textile treatment technology under development for a broad range of applications, including healthcare textiles, commercial uniforms and essential wear.

Stay Fresh Antimicrobial is an EPA-registered product that offers material protection for a wide variety of applications, for which a range of solution concentrations are available. The range of application varies widely by intended use, durability requirement, and substrate material.

Stay Fresh Antimicrobial has excellent durability. It imparts durable antimicrobial activity to the surface of a wide variety of substrates. Stay Fresh Antimicrobial suppresses the growth of algae, mold, mildew, fungi and bacteria which cause unpleasant odors, discoloration, staining, deterioration and corrosion.

http://www.quickmedtech.com/technology/stay-fresh

I am not sure why the company is silent. They need to step up and announce the patent news.

Is it possible that the float here is just 1,378,580? According to the last 10-k, that was put out in 2013, the OS was 37,346,154 as of June 30, 2013. On page 51 of that 10-k it shows insiders owning a total of 35,967,574, for a difference of 1,378,580. Furthermore, The OS had only increased by 100k shares from June 2011 to June 2013.

QMDT Patent Applications:
http://www.patentsencyclopedia.com/assignee/quick-med-technologies-inc/

QMDT's newest patent 1/24/2017:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=%22QUICK-MED+TECHnologies%22&OS=%22QUICK-MED+TECHnologies%22&RS=%22QUICK-MED+TECHnologies%22

Found this from 2013:

https://sbir.defensebusiness.org/content/static/selections/abs2012-2/dhpabs122.html

Quick Med Technologies, Inc.
902 NW 4th Street
Gainesville, FL 32601
Phone:
PI:
Topic#: (352) 379-0611
Bernd Liesenfeld
DHP12-016 Awarded: 5/13/2013
Title: Development of Technologies that Control Scar Contracture after Burn Injuries
Abstract: Current therapies to prevent scar formation and contracture of burns are minimally effective. QuickMed Technologies (QMT) proposes to develop an advanced therapy to enhance healing and prevent contraction of burn scars by combining the advanced prototype BURN- PLUS? dressing with Endoform? dermal template. BURN-PLUS is an occlusive island dressing with an adhesive apron bonded onto a super absorbent, microbicidal, pad that provides sustained release of two pre-loaded, FDA-cleared drugs: doxycycline and Kepivance?. Doxycycline is a broad spectrum antibiotic that also reduces inflammation through inhibition of tumor necrosis factor alpha (TNFa) converting enzyme (TACE) and inhibits contraction of collagen lattices by myofibroblasts through its inhibition of matrix metalloproteinases (MMPs). Kepivance is keratinocyte growth factor (KGF), which accelerates healing of skin wounds by directly stimulating proliferation and migration of epithelial cells. Endoform is a novel acellular matrix that has intact extracellular matrix (ECM) components (collagen IV, laminin, fibronectin) and growth factors (FGF2, VEGF) that increases vascularization and decreases irregular scar matrix in pig skin wounds. In this Phase I project, QMT will optimize design components of BURN-PLUS dressing and test its effectiveness alone and combined with Endoform matrix on enhancing healing and reducing scar formation and contracture of burn wounds in pigs.

Quick-Med awarded 7 govt. contracts from 2000-2015:
http://www.governmentcontractswon.com/department/defense/contractors479.asp

QUICK-MED TECHNOLOGIES, INC.
902 NW 4TH ST
GAINESVILLE, FL 32601-4285 7 $989,999

QMDT 100 million AS, 37 million OS, float(?) tiny by the looks of things.

QMDT is active with NVSOS!

http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=uqPeK5X78e8FSS496vfYYw%253d%253d&nt7=0

Found some interesting stuff on QMDT. They signed a licensing deal with a company called VIRIDIS BIOPHARMA PVT. LTD in 2010, and it looks like it's still on-going.

https://www.lawinsider.com/contracts/55sHYLC5gQ0rNazsFvLVdn/quick-med-technologies/florida/2010-07-30

I went to the VIRIDIS BIOPHARMA PVT. website, which is current, and look what I found under their products:

http://viridisbiopharma.com/index.htm

Microfoam™ and Woundguard™

These innovative dressings, available as a polyurethene foam (Microfoam™) or a 12 ply cotton gauze (Woundguard™), prevent bacterial penetration and inhibits growth within wound dressings. They are based on the cutting edge, patented non-leaching antimicrobial NIMBUS® Technology from Quick-Med Technologies, USA, which TIME magazine called one of the ‘10 Best Discoveries of 2006’. NIMBUS® is based on non-toxic, long chain polymers with high charge density that provide superior efficacy via a physical action on microbes. By destroying bacteria at the cellular level, NIMBUS® eliminates the risk of developing drug resistance. The technology is highly effective against a multitude of bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE).


http://viridisbiopharma.com/products/dressings.htm

And found this too:

Quick-Med Technologies

Quick-Med Technologies, Inc is a life sciences company focused on developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. They developed the patented NIMBUS® technology which is licensed by Viridis for the manufacture of Microfoam™ and Woundguard™.

Agreed. Just shy of a 90% move on just under 25k shares, and at different buying levels all the way up. Not much was showing on L2 under .06, or .10 for that matter. Very thin.

Look like the shares are fully locked up, very thin move up very well.

Shares appear to be very scarce here. Insiders holding.

LOOKING GOOD HERE BRO.

GRANT A US PATENT AND NOT EVEN PR IT YET. THIS IS HUGE $$$$

FDA APPROVAL THIS IS HUGE....

LOOKING TO GET IN THIS MORNING

AWESOME PLAY HERE YA.

looking good here qmdt! all we need is a pr! this has a history to run

Check out the date on this! Looks like despite the company being dark, they are still at it. No wonder the shares are still so tight.

Available from: Bernd Liesenfeld, Nov 10, 2016

https://www.researchgate.net/publication/303581393_DEVELOPMENT_OF_A_NOVEL_PEROXIDE-BASED_ANTIMICROBIAL_HYDROCOLLOID_FOR_WOUND_DRESSINGS_AND_FOR_OSTOMY_APPLICATIONS

QMDT President on Linkedin. Current!
https://www.linkedin.com/in/bernd-liesenfeld-3674725

Bernd Liesenfeld

President at Quick-Med Technologies

Gainesville, Florida Area
Biotechnology

Current Quick-Med Technologies

Previous Quick-Med Technologies

Education University of Florida

Experience

President
Quick-Med Technologies
2012 – Present (5 years)

Principal Scientist
Quick-Med Technologies
2004 – July 2012 (8 years)